BridgeBio Pharma, Inc. (BBIO) income statement
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$78.01+1.21 (+1.58%)
Close on Nov 18, 2026Market cap $15.20BP/E –Yield –
BridgeBio Pharma, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 94.3%
- Operating margin
- -38.5%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.09
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 156.9%
Valuation
- P/E ratio
- –
- Price to sales
- 16.07
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?